Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Figure 3

Comparison of LIFETEST of DMFS between IMRT concurrent with sorafenib (group A) and IMRT alone (group B).